2025 Winter School Online

Keynote Speakers

Jonathan D. Moreno PhD is the David and Lyn Silfen University Professor at the University of Pennsylvania, where he is a Penn Integrates Knowledge (PIK) professor. At Penn he is also Professor of Medical Ethics and Health Policy, of History and Sociology of Science, and of Philosophy. His most recent books are Everybody Wants to Go to Heaven but Nobody Wants to Die: Bioethics and the Transformation of Healthcare in America, co-authored with Penn president Amy Gutmann; and The Brain in Context: A Pragmatic Guide to Neuroscience, written with neuroscientist Jay Schulkin. Among Moreno’s previous books are, The Impromptu Man: J.L. Moreno and the Origins of Psychodrama Encounter Culture and the Social Network and The Body Politic which was named a Best Book of 2011 by Kirkus Reviews; Undue Risk, nominated for the Virginia Book Award; and Mind Wars, which was referenced by the screenwriter of The Bourne Legacy. He has published more than a thousand papers, articles, reviews and op-eds. Moreno’s writings have been translated into German, Japanese, Korean, Portuguese and Romanian. Moreno is senior consultant to a six-year, 10 million euro project on cold war medical science on both sides of the iron curtain, funded by the European Research Council. Moreno’s op eds have been published in venues including The New York Times, The Wall Street Journal, Science, Nature, Slate, Politico, The Hill, Foreign Affairs, Axios.com, The Huffington Post, and Psychology Today. He often appears on broadcast and online media.  He was co-host of Making the Call, an Endeavor Content podcast and was a columnist for ABCNews.com. Formerly Moreno was a senior fellow at the Center for American Progress in Washington, DC. and editor of the online magazine Science Progress. The American Journal of Bioethics has called him “the quietly most interesting bioethicist of our time.” Moreno is an elected member of the National Academy of Medicine. He has served as a staff member or adviser to many governmental and non-governmental organizations, including the UNESCO International Bioethics Committee, three U.S. presidential commissions, the Department of Defense, the Department of Homeland Security, the Department of Health and Human Services, the Centers for Disease Control, the Federal Bureau of Investigation, the Howard Hughes Medical Institute, and the Bill and Melinda Gates Foundation. In 2008-09 he served as a member of President Barack Obama’s transition team. Moreno received his Ph.D. in philosophy from Washington University in St. Louis, was an Andrew W. Mellon post-doctoral fellow, holds an honorary doctorate from Hofstra University and is a recipient of the College of William and Mary Law School Benjamin Rush Medal, the Dr. Jean Mayer Award for Global Citizenship from Tufts University, and the Penn Alumni Faculty Award of Merit.  He has held the honorary Visiting Professorship in History at the University of Kent in Canterbury, England. In 2018 the American Society for Bioethics and Humanities presented him with its Lifetime Achievement Award. Jonathan D. Moreno, PhD

Absolutely Essential: Bioethics and the Rules-Based International Order

In my new book Absolutely Essential, I explore the field of bioethics as both a creature and a key element of the post–World War II rules-based order. According to this order, international relations are to be organized according to principles of open markets, liberal democracy, and multilateral organizations. In the book I raise key questions about the future of bioethics in a changed world order, while also theorizing new ways to think about bioethics after the COVID-19 pandemic and the reordering of global alliances.

Judit Sandor PhD is a full professor at the Faculty of Political Science, Legal Studies and Gender Studies of the Central European University (CEU), Budapest. She had a bar exam in Hungary she conducted legal practice at Simmons & Simmons in London, had fellowships at McGill (Montreal), at Stanford (Palo Alto), and at Maison de sciences de l’homme (Paris), at NYU (New York, as a Global Research Fellow). In 1996 she received Ph.D. in law and political science. She was one of the founders of the first Patients’ Right Organization (‘Szószóló’) in Hungary, she was a member of the Hungarian Science and Research Ethics Council, and currently a member at the Hungarian Human Reproduction Commission. She participated in different national and international legislative, standard setting and policy making activities in the field of biomedical law and bioethics. In 2004-2005 she served as the Chief of the Bioethics Section at the UNESCO. She published seven books in the field of human rights and biomedical law. Her works appeared in different languages, including Hungarian, English, French and Portuguese. Since September 2005 she is a founding director of the Center for Ethics and Law in Biomedicine (CELAB) at the Central European University. She has completed ten European research projects (including: GeneScreen, PUG, STRATA-ETAN GROUP, GeneBanC, PRIVIREAL, PRIVILEGED, Tiss.Eu, RemediE, EULOD, NANOPLAT), founded by the European Commission in the field of biobanks, genetic data, stem cell research, organ transplantation and human reproduction. In 2014-2016 she worked at the NERRI and the EUCElLEX Projects. In 2017 she participated at the HURMUR Project and continued her work also within the IANB network, co-ordinated by the University of Rennes. In 2017-2020 she served also at the ESOF Programme Committee with the mission of organizing the Euroscience Open Forum to be held in Toulouse and in Triest. In 2019 she received the prestigeous ERC Synergy Grant with the “Leviatahan”project.

Digital Health: Bioethical and Legal Challenges

The use of artificial intelligence in health care creates many new challenges, therefore bioethics needs a more nuanced analysis in designing the normative framework for the regulation of health care applications of AI solutions. While artificial intelligence may enhance accuracy in medical diagnosis and therapies, one could reasonably foresee that the right to healthcare and the right to personalized care might be interpreted very differently in the future. For example, effective healthcare could be provided with the assistance of technology, but it may also mean that Ai-based precision medicine will not necessarily offer personal services as before. If patients are replaced by digital data in biomedical research, it will make it easier to handle huge medical databases. However, small errors may be amplified and create complex liability cases. Communication, which is also a basic element of the classical patient–doctor relationship, will also be altered when a chatbot acts as an interface and laboratory tests are interpreted by artificial intelligence instead of humans. This would presuppose much more autonomy and knowledge on the patient side, as well. Emerging technologies are often regarded as transformative technologies. Nevertheless, the way advanced technologies transform our life is not predetermined by the invention itself, but by careful and sensitive implementation, which is a multidisciplinary work and requires the engagement of society

Kalina Kamenova PhD is Founder and Research Director of Canadian Institute For Genomics And Society | Toronto. Her work integrates bioethics, science policy, and public engagement strategies to shape evidence-based decisions in health and biomedical innovation, including genomics, precision medicine, stem cell and regenerative therapies, and artificial intelligence (AI) in healthcare. As Founder and Research Director of the Canadian Institute for Genomics and Society (Genomics4S), I have advanced participatory research, ethical governance, and policy innovation in emerging biotechnologies. Partnering with leading researchers, scientists, policymakers, and industry stakeholders, I have enabled strategic collaboration on initiatives that navigate the ethical and societal dimensions of biomedical innovation. With prior leadership experience at Loyalist College’s Applied Research and Innovation Office and University of Alberta’s Centre for Public Involvement, I have also contributed to fostering cross-sectoral innovation through applied research, policy development, and strategic partnerships. My executive and management expertise spans research administration, grant development, research ethics, team-building, and stakeholder engagement. I am driven by a commitment to responsible research and innovation, ensuring inclusive public discourse around transformative scientific advancements.

Recruitment by Algorithm: Bioethical Challenges of Generative AI in Clinical Trials

The use of generative artificial intelligence (AI) in clinical trial recruitment is rapidly changing how participants are identified, engaged, and enrolled. While the technology promises efficiency and broader reach, it also raises urgent ethical concerns. First, algorithmic bias in recruitment systems may reproduce or deepen health disparities, threatening efforts to build representative and inclusive clinical studies. Second, reliance on AI-generated patient materials complicates informed consent and transparency, since tailored outputs can obscure critical risks, oversimplify complex medical information, or frame participation in ways that undermine trust. Third, the integration of AI into recruitment workflows necessitates enhanced frameworks for accountability and responsible governance. Unlike traditional recruitment processes, generative AI involves layers of opacity, raising difficult questions about responsibility for errors, bias, and participant harm. Without strong regulatory oversight, the rapid adoption of AI-driven tools risks undermining participant protections and public trust in clinical research.
Dr. Inmaculada de Melo-Martín is Professor of Medical Ethics at Weill Cornell Medical College—Cornell University. She received her undergraduate degree from the University of Oviedo, Spain and her Ph.D. in Philosophy from the University of South Florida. Dr. de Melo-Martín also did graduate work in Philosophy of Science and Philosophy of Technology at the University of Valencia, Spain. She also has a M.S. in Molecular Biology from The University of Texas at San Antonio. Her research interests include Bioethics and Philosophy of Science, and she has published widely on ethical and epistemological issues related to reproductive technologies, molecular genetics, and research ethics. Dr. de Melo-Martín’s has served on the Executive Board for the American Society for Bioethics and Humanities and the American Philosophical Association Committee on Philosophy and Medicine. In 2012 she received a Gubernatorial appointment to serve on the Ethics Committee of New York Stem Cell Board–Ethics.
Ethical Issues in Reprogenetic Technologies
Scientific and technological advances in the areas of reproduction and genetics give us new means to shape the lives of our offspring. We now have an unprecedented ability to control not just whether and when we have children but also to create different family arrangements and decide what children we want to have. These advances thus present us with a variety of important ethical concerns surrounding the creation and alteration of human life. In this session we will offer an overview of reprogenetic technologies and examine some of the ethical questions these technologies raise.
Adarsh Srivastava MBA is a seasoned professional with over 13+ years of expertise in the dynamic field of Data & Analytics. Currently serving as the Head of Data & Analytics Quality Assurance at Roche Diagnostics, he has played a pivotal role in shaping the landscape of data analytics products within the healthcare domain. His leadership has been marked by the successful spearheading of initiatives aimed at developing highly resilient data analytics solutions. Adarsh’s commitment to excellence extends beyond product development, as he has actively contributed to the establishment of a robust infrastructure and the cultivation of competencies in AI Ethics and responsible AI at Roche. Passionate and forward-thinking, Adarsh Srivastava is at the forefront of implementing trustworthy AI systems. His vision and dedication have been instrumental in propelling the organization toward a future where it is fully equipped to harness the potential of AI.   
AI & Bias: Politics, Power, and the Ethics of Research Governance
Artificial intelligence is often framed as a technical system plagued by “bias,” but the roots of bias run much deeper. They emerge not only from skewed datasets or flawed algorithms, but also from political choices about what knowledge counts, who is represented, and whose interests are served. This session explores the intersections of AI bias, politics, and research governance. Drawing on cases from healthcare and beyond, it examines how institutional structures—ethics boards, funding bodies, and regulatory regimes—shape the way bias is recognized, ignored, or reproduced in AI systems. The session will argue that bias is less a computational glitch and more a reflection of entrenched power relations, making it a bioethical issue of urgent importance. Participants will be invited to rethink research governance for the AI era, considering transparency, contextual fairness, and participatory ethics as pillars for more trustworthy and equitable innovation.